盟科药业跌3.52% 2022年上市即巅峰募10.6亿元

Core Viewpoint - Mengke Pharmaceutical's stock price has declined and is currently in a state of loss since its IPO, indicating potential challenges in market performance and investor confidence [1] Company Overview - Mengke Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 5, 2022, with an initial public offering (IPO) of 130 million shares at a price of 8.16 yuan per share [1] - The stock reached a peak price of 14.20 yuan on its first trading day, which remains the highest price since its listing [1] Financial Performance - The total funds raised from the IPO amounted to 1.0608 billion yuan, with a net amount of 959.7279 million yuan after deducting issuance costs [1] - The net funds raised were 290.1495 million yuan less than the original plan, which aimed for 1.2498774 billion yuan [1] - The total issuance costs were 101.0721 million yuan, with underwriting and sponsorship fees accounting for 79.0296 million yuan [1] Use of Proceeds - The funds raised are intended for innovative drug research and development, upgrading marketing channels and academic promotion projects, and supplementing working capital [1]